Progression of Myopic Maculopathy during 18-Year Follow-up. 2018

Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan.

To examine the progression pattern of myopic maculopathy. Retrospective, observational case series. Highly myopic patients who had been followed up for 10 years or more. Using fundus photographs, myopic features were differentiated according to Meta-analysis of Pathologic Myopia (META-PM) Study Group recommendations. Progression pattern of maculopathy. The study included 810 eyes of 432 patients (mean age, 42.3±16.8 years; mean axial length, 28.8±1.9 mm; mean follow-up, 18.7±7.1 years). The progression rate of myopic maculopathy was 47.0 per 1000 eye-years. Within the pathologic myopia (PM) group (n = 521 eyes), progression of myopic maculopathy was associated with female gender (odds ratio [OR], 2.21; P = 0.001), older age (OR, 1.03; P = 0.002), longer axial length (OR, 1.20; P = 0.007), greater axial elongation (OR, 1.45; P = 0.005), and development of parapapillary atrophy (PPA; OR, 3.14; P < 0.001). Diffuse atrophy, found in 217 eyes without choroidal neovascularization (CNV) or lacquer cracks (LCs) at baseline, progressed in 111 (51%) eyes, leading to macular diffuse atrophy (n = 64; 64/111 or 58%), patchy atrophy (n = 59; 53%), myopic CNV (n = 18; 16%), LCs (n = 9; 5%), and patchy-related macular atrophy (n = 3; 3%). Patchy atrophy, detected in 63 eyes without CNV or LCs at baseline, showed progression in 60 eyes (95%), leading to enlargement of original patchy atrophy (n = 59; 59/60 or 98%), new patchy atrophy (n = 29; 48%), CNV-related macular atrophy (n = 13; 22%), and patchy-related macular atrophy (n = 5; 8%). Of 66 eyes with LCs, 43 eyes (65%) showed progression with development of new patchy atrophy (n = 38; 38/43 or 88%) and new LCs (n = 7; 16%). Reduction in best-corrected visual acuity (BCVA) was associated mainly (all P < 0.001) with the development of CNV or CNV-related macular atrophy and enlargement of macular atrophy. The most frequent progression patterns were an extension of peripapillary diffuse atrophy to macular diffuse atrophy in diffuse atrophy, enlargement of the original atrophic lesion in patchy atrophy, and development of patchy atrophy in LCs. Main risk factors for progression were older age, longer axial length, and development of PPA.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012164 Retinal Diseases Diseases involving the RETINA. Disease, Retinal,Diseases, Retinal,Retinal Disease
D001766 Blindness The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE. Amaurosis,Bilateral Blindness,Blindness, Bilateral,Blindness, Legal,Blindness, Monocular,Blindness, Unilateral,Sudden Visual Loss,Unilateral Blindness,Blindness, Acquired,Blindness, Complete,Blindness, Hysterical,Blindness, Transient,Acquired Blindness,Amauroses,Bilateral Blindnesses,Complete Blindness,Hysterical Blindness,Legal Blindness,Monocular Blindness,Sudden Visual Losses,Transient Blindness,Visual Loss, Sudden
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005451 Fluorescein Angiography Visualization of a vascular system after intravenous injection of a fluorescein solution. The images may be photographed or televised. It is used especially in studying the retinal and uveal vasculature. Fluorescence Angiography,Fundus Fluorescence Photography,Angiography, Fluorescein,Angiography, Fluorescence,Fluorescence Photography, Fundus,Photography, Fundus Fluorescence
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
May 2006, The British journal of ophthalmology,
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
January 2021, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
January 2023, Retina (Philadelphia, Pa.),
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
July 2021, Retina (Philadelphia, Pa.),
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
March 2019, Investigative ophthalmology & visual science,
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
August 1993, Investigative ophthalmology & visual science,
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
August 2018, Ophthalmology,
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
September 2019, BMC ophthalmology,
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
March 2024, JAMA ophthalmology,
Yuxin Fang, and Tae Yokoi, and Natsuko Nagaoka, and Kosei Shinohara, and Yuka Onishi, and Tomoka Ishida, and Takeshi Yoshida, and Xian Xu, and Jost B Jonas, and Kyoko Ohno-Matsui
May 2022, Ophthalmology,
Copied contents to your clipboard!